3955 Courses delivered Online

The Level 3 Certificate in Assessing Vocational Achievement, also known as the Level 3 CAVA Assessor course, replaces the A1 course and is considered an industry-standard qualification for people looking to assess learners for accredited courses.

A 505(b)(2) New Drug Application (NDA) is a submission to the Food and Drug Administration (FDA) for approval to market a drug in the USA. It differs from a ‘stand-alone’ NDA in that some of the data on which the applicant relies to demonstrate safety and efficacy have been obtained from publicly available sources rather than from the applicant’s own studies. The applicant typically proposes to market a drug that is based on an approved reference product but modified in its formulation or uses. A 505(b)(2) NDA also differs from an Abbreviated New Drug Application (ANDA) for approval of a generic drug in that the applicant’s product need not be a duplicate of the reference listed drug. The 505(b)(2) pathway may be said to lie part-way between the ‘stand-alone’ NDA and generics pathways, offering a unique combination of advantages to developers. It facilitates the modification of drugs to address unmet medical needs. The 505(b)(2) application pathway accounts for about half of all new drug approvals in the USA.

Our Team Leader Programme is designed specifically for new & existing Team Leads & Managers in Healthcare, such as General Practice, Primary & Secondary Care. This programme gives delegates the opportunity to spend time with peers, gain new tools & techniques that enable them to develop & support their team effectively. Building confidence to be able to have more proactive & challenging conversations with team members, supporting managers and reducing escalation.